NOVA is Bittensor subnet 68 (SN68), a project in the Healthcare and Medical AI lane. Mining for medicine.
NOVA turns drug discovery into a live, decentralized contest. Miners compete to surface viable drug candidates from a 65 billion compound chemical space, with weekly protein targets refreshed by the Metanova team. The repo updated two days ago, the most recent target is an IL-6 nanobody, and the alpha is up 55.76% over
It is an educational deep dive, not a recommendation to stake. For live price, pool depth, and performance, always open the live subnet page.
What is NOVA (SN68)?
NOVA is an AI-powered drug discovery network. Miners compete each week to find molecules that bind tightly to a protein target chosen by the team, and validators re-score every submission using independent structural and binding models before paying rewards.
In plain English: Imagine a global treasure hunt where the prize is a molecule that could become a medicine. Every week the team picks a new disease-related protein. Thousands of search strategies run in parallel, and the cleanest hits get paid.
Centralized reference points: Schrödinger, Recursion Pharmaceuticals, Insilico Medicine
How miners and validators work
Like every Bittensor subnet, SN68 is a two-sided market: miners produce work, validators score it, and emissions follow those weights under the network’s dTAO economics.
- Miners compete in two tracks. In NOVA Compound, they submit candidate molecules tuned for high affinity to the weekly target, low affinity to anti-targets, and chemical novelty. In NOVA Blueprint, they instead submit search code that runs inside a standardized sandbox on an RTX 4090 against randomized targets.
- Validators re-score Compound submissions with Boltz-2 for structural fit and affinity, apply entropy bonuses for diverse chemistry, and invalidate any molecule already found earlier in the same target-week. For Blueprint, validators run the miner code, then re-score its 100-molecule output with PSICHIC.
Mechanism and design
The dual track design is what separates NOVA from a generic compute subnet. NOVA Compound is the direct competition: miners submit molecule sets each epoch, scored on target affinity, anti-target avoidance, and chemical novelty. A time-dependent entropy bonus rewards new scaffolds, and any molecule already found earlier in the same target-week is automatically invalidated, forcing continuous fresh exploration rather than miners converging on a few known winners.
NOVA Blueprint is the meta-competition. Instead of submitting molecules, miners submit search code. That code runs in a standardized sandbox for roughly 30 minutes on an RTX 4090, against randomized target and anti-target proteins revealed only after submissions close. The output, a set of 100 molecules, is then re-scored with PSICHIC. Intra-submission duplicates or molecules failing basic chemical-property checks (minimum heavy atom count, rotatable bond limits) disqualify the entire submission. The result is that NOVA pays not just for molecules, but for general-purpose molecule-finding tools.
The development picture is concentrated but steady. The public repo at metanova-labs/nova shows 583 total commits with 3 active contributors, led by cosmic-amanita. The most recent commit landed on 2026-05-20, two days before this write-up. The May commit history reads as ongoing biology work: MSA files added for proteins O15379, P05231, and Q6P6W3, a merged pull request enforcing VHH nanobody hallmark residues, a nanobody incentive proportion update, and weekly target refreshes. This is not a snapshot frozen in 2025, it is a live scoring engine being tuned each week.…
Why the project exists
- The problem it solves: Conventional drug discovery takes a decade per candidate and costs billions, with the search bottlenecked behind closed corporate pipelines. NOVA opens the early-stage molecular search to anyone with compute and a strategy.
- The opportunity: Pharma spends over 200 billion dollars a year on R&D. Even modest gains in the hit-finding stage compound into faster, cheaper preclinical pipelines.
- The Bittensor advantage: Decentralized competition means many independent search heuristics run side by side. Duplicate-invalidation rules push miners away from known scaffolds and toward chemistry no centralized lab has bothered to try.
- Traction signals: 583 commits and active weekly target rotations on the public repo, with the last commit landing two days ago. Recent work includes IL-6 nanobody target setup and enforcement of VHH hallmark residues at framework positions 49 and 50, indicating the team is tuning the scoring rules to real antibody biology rather than generic small molecules.
What stakers should check before buying alpha
Subnet storytelling is cheap. On-chain and product checks are not. Use the same framework as our subnet metrics guide:
| Check | Why |
|---|---|
| Real product / docs / repo | Separates shipping teams from narrative-only slots |
| Pool depth (TAO) | Your exit door: thin pools amplify slippage |
| Net flows (7d / 30d) | Under flow-based emissions, capital votes with its feet |
| Emission share | Whether the market is funding this subnet right now |
| Ownership concentration | Large holders can move a small alpha market |
| Immunity / deregistration | Post-immunity weak slots can lose the race (see immunity guide) |
Pull the live numbers on NOVA · SN68 rather than trusting any static screenshot in a blog post.
Risk factors
- Validation gap: Computational screening is only the first step in drug discovery. Without wet-lab partnerships to test candidates and a track record of advanced compounds, NOVA's outputs remain theoretical.
- Regulatory complexity: Drug development requires navigating FDA and EMA processes that no subnet can automate. The path from a high-affinity prediction to an approved medicine is long, slow, and capital-intensive.
- Niche audience: Pharmaceutical AI is a specialized market. Most crypto miners and TAO stakers may not recognize the value proposition, which can cap how widely the subnet is understood and held.
- Contributor concentration: Public commit activity is currently driven by a small core team, with one developer responsible for the majority of recent work. Slower bus factor on a research-heavy codebase is something to monitor.
- Competition from well-funded incumbents: Schrödinger, Recursion, Insilico Medicine and others have raised hundreds of millions for AI drug discovery, with established pharma partnerships and proprietary datasets NOVA cannot match yet.
How this fits a TAO portfolio
Many holders keep a root vs subnet split: root for calmer TAO exposure, subnets like NOVA for thematic upside (and higher variance). If you use TaoScale, you can size SN68 from your wallet without handing over custody. See non-custodial staking.
- Live market: SN68 on TaoScale
- Browse and stake: /invest
- More subnet explainers: /blog/subnets
FAQ
What does NOVA do on Bittensor?
Imagine a global treasure hunt where the prize is a molecule that could become a medicine. Every week the team picks a new disease-related protein. Thousands of search strategies run in parallel, and the cleanest hits get paid.
What is the SN68 alpha token?
When you stake TAO into subnet 68, you receive that subnet’s alpha. Its price versus TAO moves with the subnet’s pool (see what is dTAO).
How do I research NOVA before staking?
Read the mechanism above, open the official repo/docs when available, then verify pool depth, flows, and activity on SN68. Cross-check with the metrics checklist.
Is this financial advice?
No. TaoScale publishes educational explainers and live tools. Decisions to stake are yours alone.
Not financial advice. Educational overview of NOVA (SN68) compiled from public project materials and ecosystem documentation. Mechanisms and market structure change, so verify live data and official sources before acting.
